核突觸蛋白抗體

規(guī)格：1mg/1ml

英文名： Alpha-Synuclein

別名： Alpha synuclein; Alpha-synuclein, isoform NACP140; alphaSYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta comp

分子量： 14kDa

儲(chǔ)存液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce

克隆類(lèi)型：Polyclonal

亞型：IgG

純化方法：affinity purified by Protein A

**原：KLH conjugated synthetic peptide derived from human Alpha-Sy

交叉反應(yīng)：Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep, Guinea Pig,

核突觸蛋白抗體細(xì)胞定位：細(xì)胞核 細(xì)胞漿 細(xì)胞膜

產(chǎn)品介紹：background: The synucleins, including alpha-synuclein (also designated NACP for nonamyloid component precursor),beta-synuclein (also designated PNP 14 for phospho-neuroprotein 14)and gamma-synuclein (also designated persyn or BCSG1 for breast cancer-specific gene 1)are presynaptic protein abundant in neurons. alpha-synuclein, a component of Alzheimer’s disease amyloid plaques, is localized to neuronal cell bodies and synapses. Coordinate expression of alpha-synucleinand beta-synuclein may be important during hematopoetic cell differentiation. In patients with Parkinson’s disease, a mutant form of alpha-synuclein has been found and gamma-synuclein is associated with axonal pathology. Function: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. Subunit: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones. Subcellular Location: Cytoplasm. Membrane. Nucleus. Cell junction, synapse. Note=Membrane-bound in dopaminergic neurons. Tissue Specificity: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. Post-translational modifications: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity). Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure. DISEASE: Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1. Parkinson disease 1 (PARK1) [MIM:168601]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), 核突觸蛋白抗體in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. Note=The disease is caused by mutations affecting the gene represented in this entry. Parkinson disease 4 (PARK4) [MIM:605543]: A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia. Note=The disease is caused by mutations affecting the gene represented in this entry. [DISEASE] Dementia Lewy body (DLB) [MIM:127750]: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques,核突觸蛋白抗體 sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the synuclein family. Gene ID: 6622 Database links: Entrez Gene: 6622 Human Entrez Gene: 20617 Mouse Entrez Gene: 29219 Rat Omim: 163890 Human SwissProt: P37840 Human SwissProt: O55042 Mouse SwissProt: P37377 Rat Unigene: 21374 Human Unigene: 17484 Mouse Unigene: 1827 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Synuclein 包括α-Synuclein，β-Synuclein 和γ-Synuclein 是神經(jīng)細(xì)胞中富含的前突觸蛋白。α-Synuclein，Alzheimer’(AD)病淀粉樣蛋白沉積的成份之一，集中分布在神經(jīng)細(xì)胞的包體和突觸。在帕金森病人中發(fā)現(xiàn)有α-Synuclein的變異型，而γ-Synuclein與軸突病理學(xué)有關(guān)。此抗體將為L(zhǎng)ewy小體癡呆癥、Parkinson癥、AD和其它一些神經(jīng)性**提供有用的病理診斷。

核突觸蛋白抗體產(chǎn)品應(yīng)用：WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.

研究領(lǐng)域：細(xì)胞生物  神經(jīng)生物學(xué)  

儲(chǔ)存條件： Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

來(lái)源： Mouse

外觀： Lyophilized or Liquid

產(chǎn)品留言

標(biāo)題

聯(lián)系人

聯(lián)系電話(huà)

內(nèi)容

驗(yàn)證碼

點(diǎn)擊換一張

注：1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請(qǐng)您留下您的詳細(xì)聯(lián)系方式!